| HUMAN-TRIAL | evidence | Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study. | Tesamorelin | Growth hormone axis · human-rct | 2026-03-25 |
| HUMAN-TRIAL | evidence | Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. | Tesamorelin | Growth hormone axis · human-rct | 2025-06-02 |
| HUMAN-TRIAL | evidence | Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. | Tesamorelin | Growth hormone axis · human-rct · n = 38 | 2024-10-01 |
| HUMAN-TRIAL | evidence | Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease. | Tesamorelin | Growth hormone axis · human-rct · n = 61 | 2021-08-16 |
| HUMAN-TRIAL | evidence | Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease. | Tesamorelin | Liver health · human-rct · n = 61 | 2021-06-15 |
| HUMAN-TRIAL | evidence | Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. | Tesamorelin | Growth hormone axis · human-rct · n = 61 | 2021-01-23 |
| HUMAN-TRIAL | evidence | Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. | Tesamorelin | Growth hormone axis · human-rct | 2020-08-20 |
| HUMAN-TRIAL | evidence | Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. | Tesamorelin | Growth hormone axis · human-rct | 2019-12-01 |
| HUMAN-TRIAL | evidence | Comparison of visceral fat measurement by dual-energy X-ray absorptiometry to computed tomography in HIV and non-HIV. | tesamorelina | Weight & fat loss · human-observational · n = 457 | 2019-02-25 |
| HUMAN-TRIAL | evidence | The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. | Tesamorelin | human-rct | 2019-01-01 |
| HUMAN-TRIAL | evidence | Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation. | Tesamorelin | human-rct | 2017-12-01 |
| HUMAN-TRIAL | evidence | Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. | Tesamorelin | Weight & fat loss · human-observational · n = 806 | 2017-10-23 |
| HUMAN-TRIAL | evidence | Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. | Tesamorelin | Glycemic control · human-rct · n = 53 | 2017-01-01 |
| HUMAN-TRIAL | evidence | Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. | Tesamorelin | Growth hormone axis · human-observational | 2015-06-01 |
| HUMAN-TRIAL | evidence | Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. | Tesamorelin | human-rct | 2015-03-01 |
| HUMAN-TRIAL | evidence | Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. | Tesamorelin | human-rct | 2015-01-01 |
| HUMAN-TRIAL | evidence | Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. | Tesamorelin | Weight & fat loss · human-rct · n = 50 | 2014-07-23 |
| HUMAN-TRIAL | evidence | The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. | Tesamorelin | Growth hormone axis · human-rct | 2014-01-01 |
| HUMAN-TRIAL | evidence | Growth hormone-releasing hormone effects on brain gamma-aminobutyric acid levels in mild cognitive impairment and healthy aging. | Tesamorelin | human-rct | 2013-07-01 |
| HUMAN-TRIAL | evidence | Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial. | Tesamorelin | Glycemic control · human-rct · n = 77 | 2013-01-01 |
| HUMAN-TRIAL | evidence | Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. | Tesamorelin | human-rct | 2012-12-01 |
| HUMAN-TRIAL | evidence | Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. | Tesamorelin | Cognition & memory · human-rct · n = 152 | 2012-11-01 |
| HUMAN-TRIAL | evidence | Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. | Tesamorelin | Weight & fat loss · human-rct | 2012-06-01 |
| HUMAN-TRIAL | evidence | Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. | Tesamorelin | Inflammation · human-rct · n = 410 | 2011-06-19 |
| HUMAN-TRIAL | evidence | Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor. | Tesamorelin | Growth hormone axis · human-observational · n = 13 | 2011-06-01 |
| HUMAN-TRIAL | evidence | Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. | TH9507 | Weight & fat loss · human-rct · n = 806 | 2010-09-01 |
| HUMAN-TRIAL | evidence | Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. | Tesamorelin | Weight & fat loss · human-rct · n = 404 | 2010-03-01 |
| HUMAN-TRIAL | evidence | Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. | Tesamorelin | human-rct | 2008-09-12 |
| HUMAN-TRIAL | evidence | Therapeutic trial of growth hormone releasing factor in HIV patients. | Tesamorelin | human-rct | 2008-04-01 |
| HUMAN-TRIAL | evidence | Metabolic effects of a growth hormone-releasing factor in patients with HIV. | Tesamorelin | human-rct | 2007-12-06 |
| HUMAN-TRIAL | evidence | A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. | TH9507 | human-rct | 2005-08-12 |
| HUMAN-TRIAL | evidence | Body Composition and Adipose Tissue in HIV | Egrifta | n = 6 | — |
| HUMAN-TRIAL | evidence | Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® | Tesamorelin | Eye & vision health · human-rct · n = 129 | — |
| HUMAN-TRIAL | evidence | Effects of Growth Hormone Releasing Hormone in HIV | Egrifta | Weight & fat loss · human-rct · n = 54 | — |
| HUMAN-TRIAL | evidence | TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy | Egrifta | Weight & fat loss · human-rct · n = 263 | — |
| HUMAN-TRIAL | evidence | Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men | Tesamorelin | n = 15 | — |
| HUMAN-TRIAL | evidence | Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® | Tesamorelin | human-observational · n = 391 | — |
| HUMAN-TRIAL | evidence | The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment | Egrifta | Cognition & memory · human-rct · n = 22 | — |
| HUMAN-TRIAL | evidence | Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue | Tesamorelin | Weight & fat loss · human-rct | — |
| HUMAN-TRIAL | evidence | Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients | Egrifta | n = 18 | — |
| HUMAN-TRIAL | evidence | Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes | TH-9507 | Glycemic control · human-rct · n = 55 | — |
| HUMAN-TRIAL | evidence | Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia | Tesamorelin | human-rct | — |
| HUMAN-TRIAL | evidence | Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese | TH-9507 | human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting | Tesamorelin | human-rct · n = 3 | — |
| HUMAN-TRIAL | evidence | Egrifta Replacement and Sleep Disordered Breathing | Egrifta | Weight & fat loss · human-observational | — |
| HUMAN-TRIAL | evidence | SMART: Somatotrophics, Memory, and Aging Research Trial | TH-9507 | human-rct · n = 151 | — |
| HUMAN-TRIAL | evidence | TH9507 in Patients With HIV-Associated Lipodystrophy | TH-9507 | Weight & fat loss · human-rct · n = 412 | — |
| HUMAN-TRIAL | evidence | Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk | Egrifta | Weight & fat loss · human-rct · n = 51 | — |
| HUMAN-TRIAL | evidence | Tesamorelin Effects on Liver Fat and Histology in HIV | Egrifta | Liver health · human-rct · n = 61 | — |
| HUMAN-TRIAL | evidence | Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury | Egrifta | Neuroprotection · human-rct · n = 36 | — |